A
Amgen Inc. (AMGN)
NMS – Real vaqt narxi. Valyuta: USD
336.29
+6.70 (2.03%)
Yopilishda: May 12, 2026, 4:00 PM EDT
336.61
+0.32 (0.10%)
Bozordan keyin: May 12, 2026, 7:59 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
336.29
+6.70 (2.03%)
Yopilishda: May 12, 2026, 4:00 PM EDT
336.61
+0.32 (0.10%)
Bozordan keyin: May 12, 2026, 7:59 PM EDT
Amgen Inc. dunyo bo'ylab inson terapevtik vositalarini kashf etadi, ishlab chiqadi, ishlab chiqaradi va yetkazib beradi. Kompaniyaning asosiy mahsulotlari revmatoid artrit, blyashkali psoriaz va psoriatik artritni davolash uchun Enbrel; blyashkali psoriaz, psoriatik artrit va Behçet kasalligi bilan bog'liq og'iz yaralari bo'lgan kattalar bemorlarni davolash uchun Otezla; osteoporoz bilan og'rigan menopauzadagi ayollarni davolash uchun Prolia; suyak bilan bog'liq hodisalarni oldini olish uchun XGEVA; miokard infarkti, insult va koroner revaskulyarizatsiya xavfini kamaytiradigan Repatha; immun trombotsitopeniya bilan og'rigan bemorlarni davolash uchun Nplate; qaytalangan yoki refrakter ko'p miyelomali bemorlarni davolash uchun KYPROLIS; qizil qon hujayralari sonining pastligi va anemiya bilan bog'liq holatlarni davolash uchun Aranesp; menopauzadagi ayollarda osteoporozni davolash uchun EVENITY; RASning yovvoyi turi bo'lgan metastatik kolorektal rak bilan og'rigan bemorlarni davolash uchun Vectibix; o'tkir limfoblastik leykemiyali bemorlarni davolash uchun BLINCYTO; qalqonsimon ko'z kasalligini davolash uchun TEPEZZA; va surunkali refrakter podagrani davolash uchun KRYSTEXXA. Kompaniya shuningdek, PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA VA VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA VA PROCYSBI kabi boshqa mahsulotlarni ham sotadi. Kompaniya shifokorlar yoki ularning klinikalari, dializ markazlari, kasalxonalar va dorixonalar kabi sog'liqni saqlash provayderlariga xizmat ko'rsatadi. Mahsulotlarini farmatsevtik ulgurji distribyutorlar orqali tarqatadi. Kompaniya TEZSPIRE-ni ishlab chiqish va tijoratlashtirish bo'yicha AstraZeneca plc; Aimovigni ishlab chiqish va tijoratlashtirish bo'yicha BEONE MEDICINES LTD.; EVENITY-ni ishlab chiqish va tijoratlashtirish bo'yicha UCB; rocatinlimabni ishlab chiqish va tijoratlashtirish bo'yicha Kyowa Kirin Co., Ltd.; va onkologik mahsulotlarni kengaytirish va ishlab chiqish bo'yicha BeiGene, Ltd. bilan hamkorlik shartnomalariga ega. Kompaniya 1980-yilda tashkil etilgan va Kaliforniyaning Thousand Oaks shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Casey Capparelli | Executive Director of Investor Relations |
| Dr. David M. Reese M.D. | Executive VP & CTO |
| Dr. James E. Bradner M.D. | Executive Vice President of Research & Development |
| Mr. Esteban Santos | Executive Vice President of Operations |
| Mr. Howard Y. Chang M.D., Ph.D. | Senior VP of Global Research & Chief Scientific Officer |
| Mr. Matthew C. Busch | Chief Accounting Officer & VP of Finance |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-01 | 10-Q | amgn-20260331.htm |
| 2026-04-30 | 8-K | amgn-20260430.htm |
| 2026-04-22 | 8-K | amgn-20260422.htm |
| 2026-04-21 | DEFA14A | amgn_top_100_defa_14a_20.htm |
| 2026-04-15 | DEFA14A | amgn_issgl_defa_14a_2026.htm |
| 2026-04-07 | DEF 14A | d13946ddef14a.htm |
| 2026-03-31 | ARS | amgn_ars_filing_2026.pdf |
| 2026-02-13 | S-3ASR | d55489ds3asr.htm |
| 2026-02-03 | 8-K | amgn-20260203.htm |
| 2026-01-30 | 8-K | d72347d8k.htm |
| Mr. Murdo Gordon | Executive Vice President of Global Commercial Operations |
| Mr. Peter H. Griffith | Executive VP & CFO |
| Mr. Robert A. Bradway | Chairman & CEO |
| Mr. Scott Skellenger | Senior VP & Chief Information Officer |